Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.38 USD | -2.27% | +0.87% | -7.91% |
Financials (USD)
Sales 2024 * | 605M | Sales 2025 * | 609M | Capitalization | 1.95B |
---|---|---|---|---|---|
Net income 2024 * | -454M | Net income 2025 * | -358M | EV / Sales 2024 * | 2.62 x |
Net cash position 2024 * | 360M | Net cash position 2025 * | 275M | EV / Sales 2025 * | 2.74 x |
P/E ratio 2024 * |
-4.22
x | P/E ratio 2025 * |
-5.28
x | Employees | 1,022 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.21% |
Latest transcript on PTC Therapeutics, Inc.
1 day | -2.27% | ||
1 week | +0.87% | ||
Current month | -12.75% | ||
1 month | -12.06% | ||
3 months | -6.73% | ||
6 months | +9.30% | ||
Current year | -7.91% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Klein
CEO | Chief Executive Officer | 52 | 19-09-30 |
Pierre Gravier
DFI | Director of Finance/CFO | 39 | 23-07-12 |
Ellen Welch
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Glenn Steele
BRD | Director/Board Member | 79 | 15-06-14 |
Chairman | 72 | 01-07-31 | |
David Southwell
BRD | Director/Board Member | 63 | 05-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.35% | 16 M€ | -7.93% | ||
0.36% | 0 M€ | 0.00% | - | |
0.25% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 25.97 | +2.57% | 647,499 |
24-04-19 | 25.32 | +2.55% | 3,931,888 |
24-04-18 | 24.69 | -1.87% | 820,086 |
24-04-17 | 25.16 | -0.51% | 665,645 |
24-04-16 | 25.29 | -1.52% | 712,695 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.91% | 1.99B | |
-0.49% | 103B | |
+3.31% | 96.73B | |
+1.66% | 21.31B | |
-16.16% | 21.21B | |
-6.82% | 18.79B | |
-41.41% | 16.37B | |
-22.87% | 13.68B | |
+6.32% | 13.44B | |
+21.46% | 10.98B |
- Stock Market
- Equities
- PTCT Stock